Rare Tumors: Part Two.
This record reviews pediatric and adolescent adrenocortical carcinoma and colorectal cancer, emphasizing associated cancer-predisposition syndromes, surgical resection as the main treatment, use of systemic therapies in advanced disease, and molecular differences from adult tumors.
Open original publication →What the AI sees
This record reviews pediatric and adolescent adrenocortical carcinoma and colorectal cancer, emphasizing associated cancer-predisposition syndromes, surgical resection as the main treatment, use of systemic therapies in advanced disease, and molecular differences from adult tumors.
Research significance
The abstract supports specialized, syndrome-aware multidisciplinary management and indicates that distinct pediatric molecular features may inform future treatment selection; however, any benefit from pediatric-specific targeted strategies remains an inference because no particular target, intervention, cohort, or outcome is reported.
Source abstract
Adrenocortical carcinoma (ACC) and colorectal cancer (CRC) are rare tumors that can be seen in pediatric and adolescent patients. Both are associated with underlying cancer predisposition syndromes, most commonly Li-Fraumeni syndrome for ACC and familial adenomatous polyposis and Lynch syndrome for CRC. The mainstay of treatment for these diseases is surgical resection, with chemotherapy and other targeted therapies being used for advanced disease. Pediatric CRC and ACC have distinct molecular characteristics from those of their adult counterparts, and should be managed at specialized centers with a multidisciplinary approach to optimize outcomes.